BioCryst stock: Wedbush trims valuation target
Published on 10/30/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and trading context
- Wedbush retained its Outperform rating while reducing its BioCryst valuation target.
- The analyst move provides a fresh reference point for investors ahead of the company's next results update.
Wedbush cut its price target for BioCryst Pharmaceuticals on October 19, 2026, while keeping an Outperform rating. Yahoo Finance, citing MT Newswires, reported that the target was reduced from USD 20.00 to USD 18.00.
Lower target, rating unchanged
The unchanged Outperform view means Wedbush's rating did not move in parallel with the valuation target. For investors, the decision separates the analyst's directional assessment from the price level used to frame potential returns.
The target revision is an analyst estimate rather than a company forecast. It should therefore be read alongside BioCryst's operating updates, regulatory developments and the timing of its next financial release. The company's recent second-quarter revenue was reported at USD 218.25 million on its topic page, giving the market a current operating reference alongside the analyst view.
Evening trading in Europe
BioCryst Pharmaceuticals stock traded at 7.56 euros on Lang & Schwarz at 20:29 CET on Friday, October 30. Investors can follow the real-time quote of BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals at a glance
- Company: BioCryst Pharmaceuticals
- ISIN: US09058V1035
- Ticker: BCRX
- Lang & Schwarz quote: 7.56 euros on October 30, 2026, at 20:29 CET
- Wedbush target: USD 18.00, with Outperform retained
The S&P 500 offers the relevant US market backdrop for the biotechnology company.
More news and analyses are available on BioCryst Pharmaceuticals stock.
